Skip to main content
Top
Published in: Supportive Care in Cancer 7/2021

01-07-2021 | Original Article

Resilience: an essential element in head and neck cancer survivorship and quality of life

Authors: Chelsea MacDonald, Julie A. Theurer, Kevin Fung, John Yoo, Philip C. Doyle

Published in: Supportive Care in Cancer | Issue 7/2021

Login to get access

Abstract

Purpose

Individuals with head and neck cancer (HNCa) face myriad biopsychosocial challenges. Even after treatment completion, these challenges may cause continued disablement and diminished quality of life (QoL). Resilience may serve to minimize the disabling impact of HNCa and, in turn, maximize QoL. The purpose of this study was to formally assess resilience in HNCa survivors and explore its relationship with QoL.

Methods

A cross-sectional descriptive study was conducted. Forty HNCa survivors completed three validated, self-report questionnaires pertaining to the collection of resilience and QoL data. Descriptive and correlational analyses were performed.

Results

Resilience was identified in HNCa survivors and a positive correlation was found between resilience and QoL.

Conclusions

Data suggest that resilience may buffer the influence of HNCa on QoL. Thus, screening for reduced levels of resilience may proactively facilitate identification of those who are most vulnerable to the psychosocial impact of HNCa. Interventions that foster resilience may ameliorate the challenges of HNCa and maximize QoL.
Literature
19.
go back to reference Davidson JRT, Connor KM (2016) Connor-Davidson Resilience Scale (CD-RISC) Manual. Unpublished. Partly accessible at www.cd-risc.com. Accessed May 2017 Davidson JRT, Connor KM (2016) Connor-Davidson Resilience Scale (CD-RISC) Manual. Unpublished. Partly accessible at www.​cd-risc.​com. Accessed May 2017
20.
go back to reference Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 33(8):879–885. https://doi.org/10.3109/02841869409098450CrossRefPubMed Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 33(8):879–885. https://​doi.​org/​10.​3109/​0284186940909845​0CrossRefPubMed
21.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://​doi.​org/​10.​1093/​jnci/​85.​5.​365CrossRefPubMed
22.
go back to reference Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
23.
go back to reference IBM Corp (2017) IMB SPSS statistics for Windows. Armonk IBM Corp (2017) IMB SPSS statistics for Windows. Armonk
37.
go back to reference Moukarbel RV, Doyle PC, Yoo JH, Franklin JH, Day AM, Fung K (2011) Voice related quality of life (V-RQOL) outcomes in laryngectomees. Head Neck 33:31–36CrossRefPubMed Moukarbel RV, Doyle PC, Yoo JH, Franklin JH, Day AM, Fung K (2011) Voice related quality of life (V-RQOL) outcomes in laryngectomees. Head Neck 33:31–36CrossRefPubMed
39.
go back to reference Ganzer H, Rothpletz-Puglia P, Byham-Gray L, Murphy BA, Touger-Decker R (2015) The eating experience in long-term survivors of head and neck cancer: a mixed methods study. Support Care Cancer 23:3257–3268CrossRefPubMed Ganzer H, Rothpletz-Puglia P, Byham-Gray L, Murphy BA, Touger-Decker R (2015) The eating experience in long-term survivors of head and neck cancer: a mixed methods study. Support Care Cancer 23:3257–3268CrossRefPubMed
40.
go back to reference Lee Y-H, Goo-Yoshino S, Lew HL, Chi W-C, Yen C-F, Liao H-F, Chen SC, Liou TH (2020) Social participation in head and neck cancer survivors with swallowing disorder: World Health Organization Disability Assessment Schedule 2.0 study. Head Neck 42(5):905–912CrossRefPubMed Lee Y-H, Goo-Yoshino S, Lew HL, Chi W-C, Yen C-F, Liao H-F, Chen SC, Liou TH (2020) Social participation in head and neck cancer survivors with swallowing disorder: World Health Organization Disability Assessment Schedule 2.0 study. Head Neck 42(5):905–912CrossRefPubMed
Metadata
Title
Resilience: an essential element in head and neck cancer survivorship and quality of life
Authors
Chelsea MacDonald
Julie A. Theurer
Kevin Fung
John Yoo
Philip C. Doyle
Publication date
01-07-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05873-4

Other articles of this Issue 7/2021

Supportive Care in Cancer 7/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine